Other languages Toleranzia AB

Equities

TOL

SE0007438577

Delayed Nasdaq Stockholm Other stock markets 03:55:36 17/05/2024 pm IST			5-day change	1st Jan Change
0.64 ^SEK	+4.58%		+18.96%	+49.53%

23/02	Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
23/02	Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2	15/01
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies	21/12
Toleranzia AB Announces Nomination Committee	15/12
Toleranzia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27
Toleranzia AB Starts Toxicology Study of its Lead Drug Candidate TOL2	26/23/26
Toleranzia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25
Toleranzia AB Establishes a Freeze-Dried Formulation of the TOL2 Drug Product	24/23/24
Toleranzia AB Run GMP Manufacturing of Drug Candidate Tol2 for Clinical Study	21/23/21
Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2023	03/23/03
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	24/23/24
Toleranzia AB Announces Appointment of Nomination Committee	12/23/12
Toleranzia AB Announces Successful Large-Scale Production of Drug Candidate TOL2	01/22/01
Toleranzia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/22/28
Toleranzia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/22/26
Toleranzia AB Announces Positive Results for Toleranzia's Drug Candidate ToL2 Published in Reputable Scientific Journal	03/22/03
Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2022	06/22/06
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	25/22/25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Toleranzia AB

Equities

TOL

SE0007438577

Other languages

Filters